Thursday - September 4, 2025
Gibson Dunn Advises Royalty Pharma on Acquisition of Royalty Interest in Amgen's Imdelltra
August 26, 2025
LOS ANGELES, California, Aug. 26 [Category: BizLaw/Legal] -- Gibson, Dunn and Crutcher, a law firm, issued the following news:

* * *

Gibson Dunn Advises Royalty Pharma on Acquisition of Royalty Interest in Amgen's Imdelltra

*

Gibson Dunn is representing Royalty Pharma plc in its acquisition of a royalty interest in Amgen's Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for up to $950 . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products